<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[128, 133] Preservation of insulin secretion,<br>[160, 180] glycosylated hemoglobin (HbA1c), continuous glucose sensor data, insulin utilization, anthropometric measures, and patient satisfaction<br>[205, 209] mixed-meal tolerance<br>[279, 282] glycemic control,<br></td>
<td width=33%>
[12, 18] glycemic control and pancreatic -cell function<br>[128, 133] Preservation of insulin secretion,<br>[160, 182] glycosylated hemoglobin (HbA1c), continuous glucose sensor data, insulin utilization, anthropometric measures, and patient satisfaction with therapy<br>[204, 216] higher mixed-meal tolerance test-stimulated C-peptide values<br>[232, 234] glycemic control<br>[261, 263] greater satisfaction<br>[279, 282] glycemic control,<br>[290, 292] patient satisfaction<br>[309, 313] residual -cell function,<br></td>
<td width=33%>
[12, 18] glycemic control and pancreatic -cell function<br>[128, 145] Preservation of insulin secretion, measured by mixed-meal-stimulated C-peptide secretion,<br>[160, 182] glycosylated hemoglobin (HbA1c), continuous glucose sensor data, insulin utilization, anthropometric measures, and patient satisfaction with therapy<br>[204, 216] higher mixed-meal tolerance test-stimulated C-peptide values<br>[225, 229] not statistically significant.<br>[231, 234] improved glycemic control<br>[247, 253] normoglycemia, better mean HbA1c)<br>[261, 263] greater satisfaction<br>[279, 287] glycemic control, was well tolerated, and<br>[288, 292] to improved patient satisfaction<br>[309, 313] residual -cell function,<br></td>
</tr>
